Drugs / Fomivirsen
last change Jul 2002 re-read 2 minutes ago

Fomivirsen

also known as Vitravene
Developed for
cytomegalovirus retinitis
Investigated by
Ionis Pharmaceuticals, Inc.

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Withdrawn EU (EMA) Vitravene 2002-07-30 europa.eu
Approved EU (EMA) Vitravene 1999-07-29 europa.eu
Approved US (FDA) VITRAVENE PRESERVATIVE FREE 1998-08-26 fda.gov

Trials 4

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT00002356 HIV infectious disease, cytomegalovirus retinitis Ionis Pharmaceuticals, Inc. Completed No outcome recorded
Phase 2 NCT00002156 HIV infectious disease, cytomegalovirus retinitis Ionis Pharmaceuticals, Inc. Completed No outcome recorded
Phase not applicable2 trials
NCT00002355 HIV infectious disease, cytomegalovirus retinitis Ionis Pharmaceuticals, Inc. Completed No outcome recorded
NCT00002187 HIV infectious disease, cytomegalovirus retinitis Ionis Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Fomivirsen ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002156
3

NCT00002187

NCT00002355

NCT00002356

Known as Vitravene ChEMBL registry synonym — accepted as the source's own label CHEMBL1201688
Route Intravitreal intravitreal injections” NCT00002356